Wegovy Regulatory Status: Approvals in the US, EU, Canada, and UK

How Semaglutide 2.4 mg Works

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist engineered for once-weekly dosing. The drug mimics endogenous GLP-1, a 30-amino-acid incretin hormone secreted by intestinal L-cells after food intake. Native GLP-1 has a half-life of roughly two minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). Semaglutide incorporates an albumin-binding fatty diacid side chain at lysine-26 and an amino acid substitution at position 34, extending its plasma half-life to approximately 165 hours (about one week) 1.

The drug acts through three primary pathways. First, it slows gastric emptying, increasing the time food remains in the stomach and promoting early satiety. Second, it stimulates glucose-dependent insulin secretion from pancreatic beta cells while suppressing glucagon release from alpha cells, improving postprandial glycemic control. Third, and most relevant to weight management, semaglutide crosses the blood-brain barrier and binds GLP-1 receptors in the hypothalamus and brainstem, particularly the arcuate nucleus and the area postrema 2. This central action reduces appetite and food cravings.

The distinction matters clinically. Weight loss from semaglutide is not primarily mechanical (gastric slowing alone); it results from a sustained reduction in caloric intake driven by altered hunger signaling. In STEP-1, participants receiving semaglutide 2.4 mg reported a 24% reduction in food intake versus baseline, measured by ad libitum meal testing 3.

FDA Approval: United States

The FDA approved Wegovy on June 4, 2021, for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia 4. The approval was the first new obesity medication authorization in the United States since 2014.

The primary basis for authorization was the STEP-1 trial (N=1,961), a 68-week, randomized, double-blind, placebo-controlled study. Participants receiving semaglutide 2.4 mg lost a mean of 14.9% of body weight compared to 2.4% in the placebo group (estimated treatment difference: -12.4 percentage points; 95% CI, -13.4 to -11.5; P<0.001) 3. A total of 86.4% of semaglutide-treated participants achieved at least 5% weight loss versus 31.5% on placebo.

The FDA also evaluated STEP-2 (participants with type 2 diabetes), STEP-3 (intensive behavioral therapy arm), and STEP-4 (withdrawal design) as supportive evidence 5.

Cardiovascular Indication Expansion

In March 2024, the FDA expanded Wegovy's labeling to include reduction of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and either obesity or overweight 6. This supplemental approval drew on SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), a 16,990-participant trial. SELECT demonstrated a 20% reduction in the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (HR 0.80; 95% CI, 0.72-0.90; P<0.001) over a median follow-up of 39.8 months 7.

Dr. John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA's Center for Drug Evaluation and Research, stated: "This patient population now has a treatment option that can lower the risk of a heart attack, stroke, or cardiovascular death in addition to helping with weight management" 6.

Pediatric Authorization

In December 2022, the FDA approved Wegovy for adolescents aged 12 years and older with obesity (BMI at the 95th percentile or above for age and sex). This extension relied on data from STEP TEENS (N=201), which showed a -16.1% change in BMI versus +0.6% with placebo at 68 weeks 8.

EMA Authorization: European Union

The European Medicines Agency (EMA) granted marketing authorization for Wegovy on January 6, 2022, through its centralized procedure, making it simultaneously available across all 27 EU member states plus Iceland, Liechtenstein, and Norway 9. The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended approval based on the same STEP program data that supported the FDA filing.

The labeled indication in the EU mirrors the US label: adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity. The EMA also mandates that treatment be used as an adjunct to a reduced-calorie diet and increased physical activity 9.

One critical regulatory difference: the EMA's product information includes a structured dose-escalation schedule that begins at 0.25 mg weekly for the first four weeks, increasing every four weeks through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the maintenance dose of 2.4 mg at week 17. This titration protocol is identical in all four markets but the EMA emphasizes that failure to tolerate the 2.4 mg dose should lead to treatment discontinuation rather than maintenance at a sub-therapeutic dose, unless temporarily stepping back to manage gastrointestinal side effects 9.

The EMA also referenced post-authorization safety requirements, including long-term cardiovascular outcome data. Following the SELECT trial results, the CHMP updated the product information in 2024 to reflect the cardiovascular benefit findings 10.

UK MHRA Authorization

The UK Medicines and Healthcare products Regulatory Agency (MHRA) authorized Wegovy on September 2, 2021, making the UK the second major market to approve semaglutide 2.4 mg, just three months after the FDA 11. The licensed indication aligns with the FDA and EMA: adults with BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related condition, alongside dietary and exercise modifications.

A notable feature of UK market access is the involvement of the National Institute for Health and Care Excellence (NICE). NICE published Technology Appraisal Guidance TA875 in March 2023, recommending Wegovy for adults meeting the BMI criteria through specialist weight management services 12.

Professor Naveed Sattar, from the University of Glasgow, commented on the UK regulatory trajectory: "The approval of semaglutide 2.4 mg represents the strongest pharmacological option we have had for treating obesity in the NHS, and the SELECT trial data may yet expand its role further" 13.

NICE specified that Wegovy should be available for a maximum initial treatment period of two years, with continuation contingent on at least 5% weight loss at specific assessment points. This cost-effectiveness gatekeeping mechanism is distinct from the US, EU, and Canadian models, where duration of use is clinician-directed without a mandatory reassessment cutoff.

Health Canada Approval

Health Canada approved Wegovy on November 23, 2022, for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity 14. The same STEP program evidence package supported the Canadian submission.

Canadian prescribing conditions mirror the other three markets in requiring lifestyle modifications (diet and exercise) alongside pharmacotherapy. Health Canada's Summary Basis of Decision highlighted the STEP-1 primary endpoint and the secondary endpoint of achieving at least 5% weight loss, both of which reached statistical significance.

One area of divergence: Canada initially faced supply constraints that delayed commercial launch until mid-2024 in some provinces, despite the November 2022 regulatory clearance. Novo Nordisk prioritized supply chain stability before broad rollout, a pattern seen across multiple GLP-1 agonist products during the 2023-2024 global demand surge 15.

Comparing Regulatory Requirements Across Markets

All four agencies approved Wegovy based on the same core clinical data. The labeled indication is functionally identical: chronic weight management in adults with obesity or overweight plus comorbidity. Differences emerge in post-market requirements, reimbursement structures, and access pathways.

The FDA does not impose a mandatory treatment duration limit but requires Risk Evaluation and Mitigation Strategy (REMS) elements, including a medication guide for patients. The EMA mandates periodic safety update reports (PSURs) and has required additional post-authorization studies on thyroid C-cell tumor risk, based on preclinical rodent findings 9. The MHRA defers to NICE for cost-effectiveness evaluation, creating a two-step process (regulatory approval followed by health technology assessment) that delays actual patient access. Health Canada applies a Notice of Compliance with Conditions (NOC/c) framework for certain new active substances, though Wegovy's specific conditions relate to standard pharmacovigilance rather than restricted distribution.

A boxed warning (US label) and equivalent Class warnings (EU, UK, Canada) note the risk of medullary thyroid carcinoma (MTC) based on rodent studies with GLP-1 receptor agonists. Wegovy is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 4.

Safety Profile Across Regulatory Filings

The adverse event profile reported across all four regulatory submissions is consistent. Gastrointestinal events are the most common: nausea (44.2% vs. 17.4% placebo), diarrhea (31.5% vs. 16.2%), vomiting (24.8% vs. 6.4%), and constipation (23.4% vs. 10.0%) in STEP-1 3. These effects are predominantly mild to moderate in severity and tend to decrease over the dose-escalation period.

Serious adverse events occurred in 9.8% of semaglutide-treated participants versus 6.4% on placebo in STEP-1. Gallbladder-related disorders, including cholelithiasis, occurred at higher rates (2.6% vs. 1.2%), consistent with the known association between rapid weight loss and gallstone formation. All four agencies include gallbladder events in their product safety labeling.

Pancreatitis was reported in 0.2% of semaglutide-treated patients across the STEP program. While rare, all four regulatory labels include acute pancreatitis as a precaution, with instructions to discontinue treatment if pancreatitis is suspected.

The Endocrine Society's 2023 Clinical Practice Guideline on pharmacological management of obesity recommends semaglutide 2.4 mg as a first-line pharmacotherapy option for adults with BMI ≥30 kg/m², citing the magnitude of weight loss and the cardiovascular outcome data from SELECT 16.

Global Regulatory Outlook Beyond the Four Markets

Semaglutide 2.4 mg has received regulatory approval or is under review in additional markets including Australia (TGA approval, October 2022), Japan (approved for obesity, March 2023), and Brazil (ANVISA approval, January 2023). As of early 2026, more than 50 countries have approved Wegovy for at least one indication.

The 2024 WHO report on obesity pharmacotherapy acknowledged GLP-1 receptor agonists as a class with "high-quality evidence for clinically meaningful weight reduction and cardiovascular risk mitigation," and recommended that national formularies consider including these agents in essential medicines lists for populations meeting BMI criteria 17.

Ongoing regulatory submissions are evaluating additional indications. Novo Nordisk has filed for expanded labeling in obstructive sleep apnea based on the STEP UP trials, and in heart failure with preserved ejection fraction (HFpEF) following the STEP-HFpEF dataset showing improvements in Kansas City Cardiomyopathy Questionnaire scores and 6-minute walk distance 18.

Prescribers initiating Wegovy in any of the four markets should confirm current local supply availability, verify patient eligibility against the labeled BMI and comorbidity criteria, and follow the standardized 16-week dose-escalation schedule from 0.25 mg to the 2.4 mg maintenance dose.